Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part B Reference Pricing Faces 'Clinical' As Well As 'Political' Obstacles

Executive Summary

Medicare pilot program on value-based purchasing could be challenged by a lack of therapeutic consensus as much as by opposition towards reduced reimbursement.


Related Content

US Sen. Cassidy On Drug Costs: Exclusivity Based on Innovation, Reference Pricing Proposed
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Medicare Pricing Experiment Won't Extend To Part D, Senate Panel Told
Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?
CMS Suspends Part B CAP As Vendors Avoid Program; Overhaul May Follow





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts